KSKazuko Sagawa

Kazuko Sagawa

*This is an algorithmically generated author record based on publicly available information.

Kazuko Sagawa has a total of 46 co-authors. Here are the top co-authors by number of shared publications:

  • Vivek Purohit

    Translational Clinical Sciences, Pfizer Research and Development, Groton, Connecticut, 06340, U.S.A.

    4 shared publications
  • Martin E. Dowty

    Pharmacokinetics, Dynamics and Metabolism, Pfizer Research and Development, Cambridge, USA

    3 shared publications
  • Vu Le

    Global Biometrics and Data Management, Pfizer Research and Development, New York, New York, 10001, U.S.A.

    3 shared publications
  • Anas Saadeddin

    Pharmaceutical Science, Pfizer Worldwide Research and Development, Madrid, Spain

    2 shared publications
  • Aurelia Maulny

    Pharmaceutical Science, Pfizer Worldwide Research and Development, Sandwich, UK

    2 shared publications
  • Hao-Jui Hsu

    Pharmaceutical Science, Drug Product Design, Pfizer Research and Development, Groton, Connecticut, 06340, U.S.A.

    2 shared publications

Latest Publications

  • Quantitative Estimation of Clinical Intrasubject Variability of a Pharmacokinetic Parameter

    by Hao-Jui Hsu, Katrina Casteel, Samuel Yang, Vivek Purohit, Vu Le, Kazuko Sagawa

    The virtual bioequivalence (VBE) approach, which employs physiologically based pharmacokinetic (PBPK) modeling in lieu of clinical bioequivalence (BE) studies, provides a valuable alternative for the pharmaceutical industry. The VBE has the potential to substantially reduce both the time and costs associated with traditional clinical BE studies. Furthermore, this approach supports ethical principles by eliminating the need to expose healthy volunteers to investigational compounds without medical benefit. Intrasubject variability (intrasubject coefficient of variation, ICV) is a main factor for balanced cross-over design BE studies in calculating the confidence intervals for the geometric mean ratio of AUC and Cmax, which determines if bioequivalence criteria are met. Thus, it is essential to employ realistic and accurate ICV values for BE assessment through PBPK modeling. Published literature indicates that the drug properties that affect oral bioavailability exhibit a good correlation with ICV. The aim of this research is to expand drug databases to reevaluate the correlation between drug properties and clinically observed ICV for Cmax (ICV_Cmax). The results demonstrated that the dose number (dose to solubility ratio), permeability and elimination half-life are three main factors influencing ICV_Cmax. Permeability becomes a dominating factor when the value is relatively low (Papp < 0.8 × 10-6 cm/sec). In addition, PBPK modeling tools, Gastroplus and Simcyp were evaluated for their ability to predict ICV_Cmax based on drug properties and their built-in physiological variations. Both simulation tools estimated intersubject variability and ICV_Cmax similarly and underestimated ICV_Cmax compared with clinically observed ICV_Cmax.

  • Open Access

    Development of a Taste-Masked, Dose-Flexible, Multiparticulate Pediatric Dosage Form: Case Study of Crizotinib, a Challenging Pediatric Formulation

    by Jeremy A. Bartlett, Natalie Culver, Matt Santangelo, Andrew Prpich, Erica Long, Kazuko Sagawa, Ravi Shanker, Huiping Xu, Keith Wilner

    Developing pediatric dosage forms remains challenging, particularly for poorly palatable drugs, which can limit tolerability and adherence. Crizotinib, an anaplastic lymphoma kinase inhibitor used to treat rare pediatric cancers, was initially available only as an oral solution or capsules, with the solution demonstrating unacceptable taste in pediatric patients. The objectives of this work were to outline results from clinical studies supporting the crizotinib pediatric formulation development and commercialization process, summarize key clinical and formulation challenges encountered, and present lessons learned from an over-a-decade-long development process. Six clinical studies conducted in pediatric patients and healthy adult participants were collectively used to evaluate palatability, tolerability, pharmacokinetics, and bioequivalence of multiple crizotinib formulations. These studies assessed an oral solution and taste-masked microsphere formulations under fasted, fed, and proton pump inhibitor coadministration conditions, using validated palatability assessments and pharmacokinetic endpoints. Early oral solution formulations showed poor palatability, contributing to reduced tolerability and discontinuation in some pediatric patients. Taste-masked microsphere formulations improved palatability but initially showed reduced drug absorption under elevated gastric pH conditions. Reformulation with a pH-independent Opadry SGR coating resulted in a microsphere formulation that achieved acceptable palatability and consistent pharmacokinetic performance and demonstrated bioequivalence to the commercial adult capsule. This over-a-decade-long clinical development program led to the commercialization of a palatable, dose-flexible, oral solid multiparticulate pediatric formulation of crizotinib for patients with anaplastic large cell lymphoma or inflammatory myofibroblastic tumors. The clinical outcomes and development strategy described herein provide a practical framework to support future pediatric formulation development programs. gov trial registration number (date of registration): NCT00939770 (15 Jul 2009), NCT01606878 (28 May 2012), NCT02006277 (10 Dec 2013), NCT03137134 (02 May 2017), NCT03978143 (06 Jun 2019), NCT04856293 (23 Apr 2021, retrospectively registered).

  • Commentary and Review on Prospective Prediction of Bioequivalence of Oral Dosage Forms using Compendial Dissolution Testing and PBPK Modeling

    by Kazuko Sagawa, Priyanka Thipsay

    A virtual bioequivalence (VBE) approach utilizing physiologically based pharmacokinetic (PBPK) modeling presents a compelling alternative for pharmaceutica


  • Open Access

    Development of a Multi-Purpose Comprehensive Physiologically Based Pharmacokinetic Model for Crizotinib: An Example Application in Bioequivalence Assessment between Oral Solution and Granules in Pediatric Subjects

    by Kazuko Sagawa, Vivek Purohit, Vu Le, Hao-Jui Hsu, Eddie Ebrahimi, Joseph Piscitelli, Huiping Xu, Theodore Johnson

    Crizotinib exhibits a complex drug-drug interaction as it is a CYP3A4 substrate and acts as both a time-dependent inhibitor and inducer of the enzyme. Absorption of crizotinib is also complex as it exhibits a prolonged absorption phase. The primary objective of this research was to develop a comprehensive physiologically based pharmacokinetic (PBPK) model to mechanistically describe both metabolism and absorption of crizotinib. The established crizotinib adult PBPK model was extrapolated to pediatric population using the modified CYP3A4 ontogeny profile to evaluate the pharmacokinetic (PK) profile after a single dose administration of crizotinib under the fasted condition in pediatric population age between 1 to 6 years old. The model was further applied to conduct virtual bioequivalence (BE) trials including clinically observed intra-subject coefficient of variation (ICV%) in both adult and pediatric populations. In adult subjects, the estimated geometric mean ratio for AUCinf and Cmax for oral solution (OS) vs granules formulation was 98.33 and 89.94, respectively with probability of demonstrating BE in adults of 100% for AUCinf and 90.3% for Cmax. In pediatric subjects, the probability of demonstrating BE success was 99.7% for both AUCinf and Cmax. The high probability of BE was replicated with the assumed higher ICV of 29% in pediatrics for both AUCinf and Cmax. The granules (commercial formulation) can be considered BE to OS (Phase 3 clinical formulation) in adults, as well as pediatric subjects aged between 1 to 6 years old. Graphical Abstract


  • Open Access

    Virtual Bioequivalence Assessment of Tofacitinib Once Daily Modified Release Dosage Form in Pediatric Subjects

    by Kazuko Sagawa, Vivek Purohit, Vu Le, Hao-Jui Hsu, Martin E. Dowty, Susanna Tse, Cheng Chang

    Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome’s set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate release (IR) tablets, modified release (MR) tablets and IR solution. A once daily MR microsphere formulation was developed for pediatric patients. Previously, bioequivalence (BE) between the 10 mg once daily (QD) MR microsphere formulation and 5 mg twice daily (BID) IR solution has been established with PBPK virtual BE trials (VBE) in place of a clinical BE trial in healthy adult population. In this research, the PBPK model based VBE approach was extended to pediatric population. Pediatric PBPK model verification was conducted by first examining predicted vs observed demographic information such as body weight (BWT) and glomerular filtration rate (GFR). After confirming the alignment in demographic background between clinical study participants vs virtual pediatric subjects, multiple ontogeny profiles for CYP3A4 and CYP2C19 were examined. The established model predicted AUC and Cmax within 1.5-fold of observed values for multiple trials, age groups and formulations. Lastly, VBE trials in pediatric subjects were conducted with PBPK model generated pharmacokinetic (PK) parameter values with clinically observed intra-subject coefficient of variation (ICV) in adults. Since ICV in pediatric population is unknown, the sensitivity around ICV was also evaluated to assess the BE risk between IR solution and MR microsphere formulation in pediatric population. The results demonstrated that the IR oral solution BID and MR microsphere formulation QD are BE in pediatric population.


  • Open Access

    Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified‐Release Dosage Form

    by Vivek Purohit, Kazuko Sagawa, Hao‐Jui Hsu, Joseph Kushner, Martin E. Dowty, Susanna Tse, Jian Lin, Andrew Blanchard, Arnab Mukherjee, Vu Le, et al.

    Tofacitinib is a potent, selective inhibitor of the Janus kinase (JAK) family of kinases with a high degree of selectivity within the human genome's set of protein kinases. Currently approved formulations for tofacitinib citrate are immediate‐release (IR) tablets, modified‐release (MR) tablets, and IR solution. A once daily MR microsphere formulation was developed for use in pediatric patients. Demonstration of bioequivalence (BE) between the 10 mg once daily (q.d.) MR microsphere formulation and 5 mg twice daily (b.i.d.) IR solution is needed to enable the exposure–response analyses‐based bridging to support regulatory approval. To assess BE between MR microsphere and IR solution, an innovative approach was utilized with physiologically‐based pharmacokinetic (PBPK) virtual BE trials (VBE) in lieu of a clinical BE trial. A PBPK model was developed to characterize the absorption of different formulations of tofacitinib using Simcyp ADAM module. VBE trials were conducted by simulating PK profiles using the verified PBPK model and integrating the clinically observed intrasubject coefficient of variation (ICV) where BE was assessed with a predetermined sample size and prespecified criteria. The VBE trials demonstrated BE between IR solution 5 mg b.i.d. and MR microsphere 10 mg q.d. after a single dose on day 1 and after multiple doses on day 5. This research presents an innovative approach that incorporates clinically observed ICV in PBPK model‐based VBE trials, which could reduce unnecessary drug exposure to healthy volunteers and streamline new formulation development strategies.


  • Open Access

    Correction: Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

    by Anas Saadeddin, Vivek Purohit, Yeamin Huh, Mei Wong, Aurelia Maulny, Martin E. Dowty, Kazuko Sagawa

  • Open Access

    Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model

    by Anas Saadeddin, Vivek Purohit, Yeamin Huh, Mei Wong, Aurelia Maulny, Martin E. Dowty, Kazuko Sagawa

    Ritlecitinib, an orally available Janus kinase 3 and tyrosine kinase inhibitor being developed for the treatment of alopecia areata (AA), is highly soluble across the physiological pH range at the therapeutic dose. As such, it is expected to dissolve rapidly in any in vitro dissolution conditions. However, in vitro dissolution data showed slower dissolution for 100-mg capsules, used for the clinical bioequivalence (BE) study, compared with proposed commercial 50-mg capsules. Hence, a biowaiver for the lower 50-mg strength using comparable multimedia dissolution based on the f2 similarity factor was not possible. The in vivo relevance of this observed in vitro dissolution profile was evaluated with a physiologically based pharmacokinetic (PBPK) model. This report describes the development, verification, and application of the ritlecitinib PBPK model to translate observed in vitro dissolution data to an in vivo PK profile for ritlecitinib capsule formulations. Virtual BE (VBE) trials were conducted using the Simcyp VBE module, including the model-predicted within-subject variability or intra-subject coefficient of variation (ICV). The results showed the predicted ICV was predicted to be smaller than observed clinical ICV, resulting in a more optimistic BE risk assessment. Additional VBE assessment was conducted by incorporating clinically observed ICV. The VBE trial results including clinically observed ICV demonstrated that proposed commercial 50-mg capsules vs clinical 100-mg capsules were bioequivalent, with > 90% probability of success. This study demonstrates a PBPK model–based biowaiver for a clinical BE study while introducing a novel method to integrate clinically observed ICV into VBE trials with PBPK models. Trial registration: NCT02309827, NCT02684760, NCT04004663, NCT04390776, NCT05040295, NCT05128058. Graphical Abstract


  • Fed and fasted gastric pH and gastric residence time in conscious beagle dogs

    by Kazuko Sagawa, Fasheng Li, Ryan Liese, Steven C. Sutton